4.8 Article

Probing protein flexibility reveals a mechanism for selective promiscuity

Journal

ELIFE
Volume 6, Issue -, Pages -

Publisher

ELIFE SCIENCES PUBLICATIONS LTD
DOI: 10.7554/eLife.22889

Keywords

-

Categories

Funding

  1. National Science Foundation [1247842]
  2. National Institutes of Health [GM097082]
  3. Direct For Education and Human Resources
  4. Division Of Graduate Education [1247842] Funding Source: National Science Foundation

Ask authors/readers for more resources

Many eukaryotic regulatory proteins adopt distinct bound and unbound conformations, and use this structural flexibility to bind specifically to multiple partners. However, we lack an understanding of how an interface can select some ligands, but not others. Here, we present a molecular dynamics approach to identify and quantitatively evaluate the interactions responsible for this selective promiscuity. We apply this approach to the anticancer target PD-1 and its ligands PD-L1 and PD-L2. We discover that while unbound PD-1 exhibits a hard-to-drug hydrophilic interface, conserved specific triggers encoded in the cognate ligands activate a promiscuous binding pathway that reveals a flexible hydrophobic binding cavity. Specificity is then established by additional contacts that stabilize the PD-1 cavity into distinct bound-like modes. Collectively, our studies provide insight into the structural basis and evolution of multiple binding partners, and also suggest a biophysical approach to exploit innate binding pathways to drug seemingly undruggable targets.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Biochemical Research Methods

Predicting protein targets for drug-like compounds using transcriptomics

Nicolas A. Pabon, Yan Xia, Samuel K. Estabrooks, Zhaofeng Ye, Amanda K. Herbrand, Evelyn Suss, Ricardo M. Biondi, Victoria A. Assimon, Jason E. Gestwicki, Jeffrey L. Brodsky, Carlos J. Camacho, Ziv Bar-Joseph

PLOS COMPUTATIONAL BIOLOGY (2018)

Article Cell Biology

Novel FOXM1 inhibitor identified via gene network analysis induces autophagic FOXM1 degradation to overcome chemoresistance of human cancer cells

Mikhail S. Chesnokov, Marianna Halasi, Soheila Borhani, Zarema Arbieva, Binal N. Shah, Rick Oerlemans, Irum Khan, Carlos J. Camacho, Andrei L. Gartel

Summary: STL427944 selectively suppresses FOXM1 by inducing its relocalization and subsequent degradation, leading to increased sensitivity of cancer cells to conventional chemotherapeutic treatments.

CELL DEATH & DISEASE (2021)

Article Biochemistry & Molecular Biology

Differential regulation of MAP2 by phosphorylation events in proline-rich versus C-terminal domains

R. A. Degiosio, P. G. Needham, O. A. Andrews, H. Tristan, M. J. Grubisha, J. L. Brodsky, C. Camacho, R. A. Sweet

Summary: MAP2 phosphorylation plays a critical role in regulating cytoskeletal functions in neurons. Recent research has shown that phosphorylation of MAP2 in the proline-rich and C-terminal domains of the protein affects cellular functions including microtubule assembly, microtubule binding, actin binding, and actin polymerization.

FASEB JOURNAL (2023)

No Data Available